Apricell Biotechnology
San Jose, United States· Est.
Apricell delivers a turnkey organoid‑on‑a‑Plate platform that accelerates oncology drug screening with human‑relevant 3‑D models.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Apricell delivers a turnkey organoid‑on‑a‑Plate platform that accelerates oncology drug screening with human‑relevant 3‑D models.
Oncology
Technology Platform
Hydrogel‑based Organoid‑on‑a‑Plate inserts that enable uniform 3‑D spheroid formation, ECM embedding, drug exposure, and in‑situ histological analysis within standard multi‑well plates.
Opportunities
Expanding into immuno‑oncology and patient‑derived organoid screening, and adding AI‑driven analytics could unlock new revenue streams and deepen pharma collaborations.
Risk Factors
Adoption may be slowed by entrenched 2‑D workflows, need for extensive validation, and competition from established organoid platform vendors.
Competitive Landscape
Key competitors include Hubrecht, Emulate, and MIMETAS; Apricell differentiates itself through its all‑in‑one inserts that reduce handling steps and preserve sample integrity.